OPA1 and breast carcinoma: Withaferin A has been reported to inhibit mitochondrial fusion and reduce mitochondrial volume, leading to a lower regulation of mitofusin1, mitofusin2, and complete optical atrophy protein1 (OPA1) while also decreasing the mitochondrial fission regulation protein dynamin-related protein1 (DRP1) and the levels of OPA1 in breast cancer cells [84].